Sugi Predict

Sugi Predict / Compounds / SCHEMBL28060

SCHEMBL28060

SCHEMBL28060

Nc1ccc(Cl)cc1C(=O)c1ccncc1

nearest known ligand 0.73

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ RECQL P46063 1/20 0.57
▸ CCR9 P51686 5/20 0.49
▸ KMT2A Q03164 3/20 0.49
▸ MEN1 O00255 2/20 0.49
▸ POLB P06746 2/20 0.49
▸ RAB9A P51151 2/20 0.49
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ FADS1 O60427 1/20 0.48
▸ MAPT P10636 2/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ GFER P55789 1/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ GCK P35557 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31366630 1.00 RECQL (0.57) RECQLCCR9KMT2AMEN1POLB
SCHEMBL14230519 0.87 BRAF (0.48) RECQLCCR9KMT2AMEN1POLB
SCHEMBL344131 0.87 SMN1; SMN2 (0.51) CCR9KMT2AMEN1POLBRAB9A
SCHEMBL6351799 0.86 RECQL (0.64) RECQLKMT2AMEN1POLBRAB9A
SCHEMBL30484136 0.84 RECQL (0.67) RECQLKMT2APOLBSMN1; SMN2MAPT
SCHEMBL31000389 0.84 RECQL (0.67) RECQLKMT2APOLBSMN1; SMN2MAPT
SCHEMBL145366 0.84 RECQL (0.67) RECQLKMT2APOLBSMN1; SMN2MAPT
SCHEMBL3481832 0.83 JAK2 (0.59) CCR9KMT2AMEN1POLBRAB9A
SCHEMBL12653273 0.83 RECQL (0.60) RECQLKMT2AMEN1POLBRAB9A
Hydrazine SCHEMBL11821861 0.83 RECQL (0.65) RECQLKMT2APOLBSMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1798223-B2 Aryl sulfonamides CHEMOCENTRYX INC (US) 2014-07-30 — — EP claimed
EP-1798223-B1 Aryl sulfonamides CHEMOCENTRYX INC (US) 2011-07-20 — — EP claimed
US-20250197360-A1 NOVEL DIAZEPINES THAT TARGET YELLOW FEVER VIRUS NON-STRUCTURAL 4B (NS4B) PROTEIN AND THEIR METHOD OF USE BARUCH S. BLUMBERG INSTITUTE 2025-06-19 — — US disclosed
WO-2023172726-A1 NOVEL DIAZEPINES THAT TARGET YELLOW FEVER VIRUS NON-STRUCTURAL 4B (NS4B) PROTEIN AND THEIR METHOD OF USE BARUCH S. BLUMBERG INSTITUTE (US) 2023-09-14 — — WO disclosed
WO-2023172726-A1 NOVEL DIAZEPINES THAT TARGET YELLOW FEVER VIRUS NON-STRUCTURAL 4B (NS4B) PROTEIN AND THEIR METHOD OF USE BARUCH S. BLUMBERG INSTITUTE (US) 2023-09-14 — — WO disclosed
US-11433061-B2 Heteroaryl sulfonamides and CCR2/CCR9 CHEMOCENTRYX, INC. (US) 2022-09-06 — — US disclosed
US-11433061-B2 Heteroaryl sulfonamides and CCR2/CCR9 CHEMOCENTRYX, INC. (US) 2022-09-06 — — US disclosed
EP-2968360-B1 QUINOLINONE DERIVATIVES FOR THE INHIBITION OF BROMODOMAIN-CONTAINING PROTEINS CONVERGENE LLC (US) 2021-01-20 — — EP disclosed
US-10717739-B2 Methods and compositions for inhibition of bromodomain-containing proteins CONVERGENE LLC (US) 2020-07-21 — — US disclosed
US-20200147066-A1 Heteroaryl Sulfonamides and CCR2/CCR9 CHEMOCENTRYX, INC. 2020-05-14 — — US disclosed
US-20200147066-A1 Heteroaryl Sulfonamides and CCR2/CCR9 CHEMOCENTRYX, INC. 2020-05-14 — — US disclosed
US-20050049274-A1 Quinolinone derivatives as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2005-03-03 — — US disclosed
EP-1507756-A1 CCR9 INHIBITORS AND METHODS OF USE THEREOF Millennium Pharmaceuticals, Inc. (US) 2005-02-23 — — EP disclosed
WO-2005009967-A2 QUINOLINONE DERIVATIVES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2005-02-03 — — WO disclosed
US-20040171654-A1 Aryl sulfonamides CHEMOCENTRYX, INC. 2004-09-02 — — US disclosed
WO-2004046092-A2 ARYL SULFONAMIDES CHEMOCENTRYX (US) 2004-06-03 — — WO disclosed
US-20040038976-A1 CCR9 inhibitors and methods of use thereof MILLENNIUM PHARMACEUTICALS, INC. 2004-02-26 — — US disclosed
WO-2003099773-A1 CCR9 INHIBITORS AND METHODS OF USE THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2003-12-04 — — WO disclosed
WO-1989010924-A1 INDAZOLE DERIVATIVES NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1989-11-16 — — WO disclosed
US-4830943-A Bisazo compounds and electrophotographic photoconductors comprising the bisazo compounds RICOH COMPANY, LTD. (JP) 1989-05-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11433061-B2 Heteroaryl sulfonamides and CCR2/CCR9 CCR2, CCR9, CCR1 RECQL 4749/4885CCR9 2/4885KMT2A 2475/4885
US-10717739-B2 Methods and compositions for inhibition of bromodomain-containing proteins BRPF3, BRD3, BRDT RECQL 1552/4885CCR9 3663/4885KMT2A 1037/4885
US-20040171654-A1 Aryl sulfonamides CCR9, CCR1, CCR2 RECQL 4746/4885CCR9 1/4885KMT2A 2760/4885
US-20050049274-A1 Quinolinone derivatives as inhibitors of c-fms kinase FLT3, ABL1, FES RECQL 838/4885CCR9 2295/4885KMT2A 1469/4885
US-20200147066-A1 Heteroaryl Sulfonamides and CCR2/CCR9 CCR2, CCR9, CCR1 RECQL 4749/4885CCR9 2/4885KMT2A 2475/4885
US-20040038976-A1 CCR9 inhibitors and methods of use thereof CCR9, CCR1, CCR4 RECQL 3618/4885CCR9 1/4885KMT2A 4473/4885
US-20250197360-A1 NOVEL DIAZEPINES THAT TARGET YELLOW FEVER VIRUS NON-STRUCTURAL 4B (NS4B) PROTEIN AND THEIR METHOD OF USE CUL4B, BRD4, CUL4A RECQL 390/4885CCR9 1793/4885KMT2A 993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.